Decitabine

SKU: orb1308400

Featured

Description

Decitabine is an orally active deoxycytidine analog and DNA methyltransferase inhibitor. It exhibits antitumor and antimetabolic activity by inducing DNA hypomethylation, leading to cell cycle arrest and apoptosis in both in vitro and in vivo cancer research models.

Research Area

Epigenetics & Chromatin, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	2353-33-5
MW	228.2
Purity	>98%
Formula	C₈H₁₂N₄O₄
SMILES	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Target	Methyltransferase
Solubility	Soluble in DMSO (up to 25 mg/ml) or in Water (up to 11 mg/ml).

Bioactivity

−

Target IC50	MDA-MB-231 cells proliferation:4 μM
In Vivo	METHODS: To assay antitumor activity in vivo, Decitabine (0.4 mg/kg) was injected intraperitoneally into NSG mice harboring the ALL tumors SEM-ffluc-GFP or RS4;11-ffluc-GFP once daily for thirty days. RESULTS: Decitabine significantly delayed leukemia cell proliferation in SEM-ffluc-GFP and RS4-ffluc-derived xenograft models. METHODS: To assay anti-tumor activity in vivo, Decitabine (0.8 mg/kg) was intraperitoneally injected into Balb-c nu/nu mice harboring the human cholangiocarcinoma tumor TFK-1 once a day for fourteen days. RESULTS: In TFK-1 mouse xenografts, Decitabine delayed tumor growth and increased survival in homozygous mice. Read more...
In Vitro	METHODS: Human acute leukemia cells molt4 were treated with Decitabine (0.00625-100 μM) for 24-96 h. Cell proliferation was detected by CCK-8. RESULTS: Decitabine inhibited the proliferation of molt4 cells in a dose- and time-dependent manner, with IC50s of 84.461 μM and 10.113 μM for 72 h and 96 h treatment, respectively. METHODS: Human BCP-ALL cells SEM and RS4;11 were treated with Decitabine (1000 nM) for 72 h, and the cell cycle was detected by Flow Cytometry. RESULTS: Decitabine induced G0/G1 arrest in SEM cells, and the cell cycle of RS4;11 was not affected by Decitabine. Read more...
Cell Research	For cell cycle analysis, KARPAS-299 cells were incubated for 24 h with 1 μM of 5-aza-CdR in RPMI and grown for 4 days in fresh RPMI only. Then, 105–106 cells were suspended in 500 μl PI-buffer (0.1% Na–citrate dihydrate, 0.1% Triton X-100, 0.1% RNAse (DNAse free) in PBS). Propidium–iodide (ROTH, dissolved in PBS) was added to a concentration of 10 μg/ml and the cells were incubated for 30 min at 37 °C. The analysis was performed on a flow cytometer using the BD FACS Diva Software. Three independent samples of 5-aza-CdR treated and PBS controls were analyzed. Descriptive statistics for analysis are reported as mean ± SEM . Read more...
Animal Research	For xenografts, NOD.CB17-Prkdc scid/NCrHsd (NOD/SCID, Harlan Laboratories) mice were used. KARPAS-299 human cells were grown as described above, dissolved in sterile PBS to a concentration of 1×107 cells/ml and inoculated subcutaneously (1×10^6 cells/injection) into the right and left flanks of the mice. Tumor range was followed measuring tumor length and tumor width with a calliper. Mice weighed approximately 25 g at the beginning of the therapy. 5-Aza-CdR was dissolved in sterile PBS and was administered intraperitoneally (i.p.). Each mouse received 2.5 mg/kg/mouse per treatment. Control mice were administered 100 μl of sterile PBS. Therapies were adjusted regarding start and duration of the treatment in order to obtain optimal treatment procedures. In schedule A, three mice were treated with 5-aza-CdR 11 days after inoculation, when tumor size was approximately 1 cm2. The control group contained two mice. The mice received 5-aza-CdR or PBS every day for eight days. In schedule B, two mice were treated with 5-aza-CdR three days after inoculation and three mice five days after inoculation when tumors were not or just palpable. 5-Aza-CdR was administered every other day for five times to each mouse. The control group contained two mice . Read more...

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

5-AzadCyD; NSC-127716

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

451668 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Decitabine (orb1308400)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	>98%
CAS Number:	1263293-37-3
MW:	648.6
Formula:	C₂₈H₃₁F₃N₈O₇

Purity:	>98%
CAS Number:	3084407-00-8
MW:	390.79
Formula:	C₁₉H₁₆ClFN₂O₄

Purity:	≥ 95% (HPLC)
CAS Number:	72052-96-1
MW:	Theoretical MW: 468.14 g/mol (free acid); Detected MW: 467.98 g/mol (free acid)
Formula:	C₈H₁₅N₄O₁₃P₃

MW:	304.68
Formula:	C₉H₁₅ClF₂N₂O₅

Decitabine

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Onvansertib fumarate [orb1910372]

Dac590 [orb3033149]

5-Aza-dCTP [orb533077]

5-Aza-3'-beta-methylcytidine [orb1907417]

Cedazuridine hydrochloride [orb1689319]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Decitabine (orb1308400)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors